About the audit
The audit was a major success. The care of more than 1000 people with lupus was assessed, resulting in the largest ever nationwide audit of a rare rheumatic disease. Units in four main regions took part - the North West, North East and the West and East Midlands; 18 additional units from across the rest of the UK also joined in.
The audit used standards derived from our guideline, the NICE Technology Appraisal for Belimumab in SLE and the NHS England Commissioning Policy for Rituximab in SLE.
Results for participating units were benchmarked against the results for the total audit population. Compliance targets for each audit standard were developed by the audit working group. The analysis was undertaken by Dr Fiona Pearce (Clinical Lecturer in Rheumatology), with local reports compiled by the lead Specialty Registrar for the audit in participating regions and units.